Neumora Therapeutics, a clinical-stage biotechnology company, reported a narrowing net loss for the second quarter of 2026 as it reduced operating expenses and realigned its leadership team. The company remains pre-revenue, focusing entirely on advancing its neuroscience pipeline with a cash position that supports operations into the third quarter of 2027. Significant progress was reported across the NLRP3 and M4 PAM programs, with multiple clinical data readouts expected by year-end.
Key Highlights
- Net loss narrowed to $43.1 million, or $0.23 per share, compared to a loss of $52.7 million, or $0.33 per share, in the same period last year.
- Total operating expenses fell 22% to $42.2 million, primarily due to a $9.4 million reduction in R&D spending from lower clinical trial and personnel-related costs.
- Pipeline catalysts include the submission of an IND for NMRA-215 in obesity by the fourth quarter of 2026 and Phase 1 schizophrenia data for NMRA-898 in the second half of 2026.